Key result
A biolimus-eluting stent showed no significant difference in cardiac death and MI compared to a bare metal stent (5.7% vs 10.6%; P=0.30), but significantly reduced TVR (1.9% vs 8.5%; P=0.04).
Why the study?
Does a biolimus-eluting biodegradable polymer-coated stent reduce cardiac death, myocardial infarction, or target vessel revascularization compared to a bare metal stent in patients with acute myocardial infarction?
Observational (n=200)
No
Does a biolimus-eluting biodegradable polymer-coated stent reduce cardiac death, myocardial infarction, or target vessel revascularization compared to a bare metal stent in patients with acute myocardial infarction?
Absolute Event Rate: 5.7% vs 10.6%
p-value: p=0.30
In patients with acute myocardial infarction, the use of a biolimus-eluting biodegradable polymer-coated stent significantly reduces the rate of target vessel revascularization compared to a bare metal stent without increasing safety risks.
AIMS: We evaluated the efficacy and safety of a biolimus- eluting biodegradable polymer-coated stent (BES) in patients with ST-segment elevation and non ST-segment elevation acute myocardial infarction (AMI). METHODS AND RESULTS: This was an observational study involving a single centre patient registry. We compared the rates of cardiac death, myocardial infarction, target vessel revascularization (TVR) and composite end point of cardiac death and myocardial infarction at 24 months in 106 patients who received BES versus 94 patients who received an otherwise similar bare metal stent (BMS) during percutaneous coronary intervention for AMI. There was no significant difference in the rate of cardiac death (0.9% versus 7.4%; P = 0.09), myocardial infarction (4.7% versus 3.2%; P = 0.69), stent thrombosis (0.9% versus 3.2%; P = 0.30) or cardiac death and myocardial infarction (5.7% versus 10.6%; P = 0.30) between the two groups. The rate of TVR was significantly higher in the BMS group (1.9% versus 8.5%; P = 0.04), with patients receiving BMS being four times more likely to require TVR. CONCLUSION: The use of BES in selected patients with AMI appears to be safe and is associated with significantly reduced rate of TVR, when compared with an otherwise similar BMS.
No takes yet. Share an insight, caveat, or question.
Chia et al. (2011) conducted an observational in Acute myocardial infarction (AMI) (n=200). Biolimus-eluting biodegradable polymer-coated stent (BES) vs. Bare metal stent (BMS) was evaluated on Composite end point of cardiac death and myocardial infarction (p=0.30). A biolimus-eluting stent showed no significant difference in cardiac death and MI compared to a bare metal stent (5.7% vs 10.6%; P=0.30), but significantly reduced TVR (1.9% vs 8.5%; P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: